Improved procedure for the the determination of rofecoxib in human plasma involving 96-well solid-phase extraction and fluorescence detection
- 7 September 2001
- journal article
- Published by Elsevier in Journal of Chromatography A
- Vol. 949 (1-2) , 83-89
- https://doi.org/10.1016/s0021-9673(01)01221-3
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Determination of Rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detectionJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitorBioorganic & Medicinal Chemistry Letters, 1999
- Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1999